HOME
SEARCH
RSS FEED
SUBSCRIBE
Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A
Case ID:
TAB-1421
Web Published:
12/6/2022
Description:
Two chimpanzee mAbs specifically reacted with light chain of the botulinum neurotoxin A and neutralize the toxin in the mouse model. They can be used for emergency prophylaxis and treatment of either naturally acquired or terrorist associated botulism. Since the sequence of chimpanzee immune globulin is virtually identical to that of humans, the MAbs are not expected to have problems in repeated administration as equine antibodies. They can also be used for rapid diagnosis of botulinum neurotoxin A.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Neutralizing_Monoclonal_Antibodies_t o_Botulinum_Neurotoxin_Type_A
Category(s):
Licensing
Research Materials
Rare / Neglected Diseases
Diagnostics
Therapeutics
Vaccines
Immunology
Infectious Disease
Antibodies
Bookmark this page
Download as PDF
For Information, Contact:
Peter Soukas
Technology Licensing Specialist/TTPS
NIH Technology Transfer
301-496-2644
peter.soukas@nih.gov
Inventors:
Robert Purcell
Suzanne Emerson
Zhaochun Chen
Keywords:
Botulinum
DB3XXX
DBXXXX
DXXXXX
Hybridoma
Listed LPM Chang as of 4/15/2015
mabs
Neurotoxin
Neutralizing
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
RM
UA1XXX
VJXXXX
WAXXXX
WIXXXX
XAXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum